Company: IgGenix, Inc.
Job title: Chief Executive Officer
Developing Antibody-Based Approaches to Reduce Downstream Allergenic Responses 2:00 pm
Re-engineering Ig-E antibodies to directly block the molecules in underlying disease Potential future use of monoclonal antibody therapeutics to address specific allergies with high affinity Effects of addressing key allergens directly on safety and mechanism of actionRead more
day: Day One